



Manhattan Scientifics, Inc.

Ticker: MHTX (OTCQB)

Corporate Profile

as of December 30, 2015

Manhattan Scientifics, Inc., ("MHTX") together with its subsidiaries, focuses on commercialization of disruptive technologies in the nano-medicine space. Based in New Mexico, and led by CEO Emmanuel Tsoupanararis and Chairman Marvin Maslow the Company creates shareholder value by capitalizing on acquired technologies or patented inventions from which significant profits can be earned primarily through licensing. Currently, MHTX's primary business is focused on a new innovative nano-medicine technology (MRX™ technology) which, if eventually approved for human use, could become a new paradigm in early stage cancer detection and diagnosis. The firm's goal is to develop the technology and partner with one or more of the leading companies in the medical imaging market, e.g. MRI and PET scan manufacturers.

The Company's combined intellectual property and technology assets make them well positioned to capitalize on the estimated \$350 billion global medical device industry, of which the United States is the world leader by market size, with total revenue of around \$110 billion (source: www.mddionline.com). Cancer diagnostics is estimated at a \$100 billion market world-wide with growth rates of over 7% for imaging technologies, positioning MHTX for future growth. The early cancer detection technology is being developed by the Company's Senior Scientific LLC subsidiary, led by Robert Proulx, President and COO. Through their collaboration with the MD Anderson Cancer Center, among others, Manhattan Scientifics could achieve commercialization or licensing partnerships partnership in the foreseeable future.

The patented Magnetic Relaxometry technology (MRX™) is potentially capable of finding cancers two to three years earlier than other known methods. Magnetic Relaxometry is a simple and highly sensitive way to measure the magnetic attributes of nanoparticles that shift and "relax" after having been subjected to a low magnetic field. The nanoparticles are designed to attach themselves to cancer cells and the MRX™ detector can then differentiate the location and number of nanoparticles that have attached to the cancerous cells thus allowing for much earlier detection. The binding element of the nanoparticles is a function of the particles being coated with known antibodies for the target disease and can be administered with simple IV injection procedures. In 2015 the Company established a nanoparticle synthesis manufacturing facility enabling Senior Scientific to now produce their own in-house nanoparticles, and paving the way to be able to control the supply for the critical component of the cancer test consumable. It is the classic razor-razor blade-marketing theme.

The MRX™ detection system is expected to enable earlier detection, and be much more precise and more cost effective than current technologies such as MRI, PET, X-ray and conventional imaging technologies. Lower equipment and build out costs could increase the number of medical practitioners and facilities that can utilize the technology thus broadening the market for the Company's commercial partners and increasing revenues for the firm. MHTX has patents issued (U.S. and international) on the core MRX™ technology allowing MHTX to offer both the MRX™ instrument and their PrecisionMRX™ nanoparticles (i.e. razor and razor blade) expanding the sales and licensing opportunities.

MHTX was recently able to significantly improve its balance sheet with the infusion of \$8 million dollars in cash and other assets including IP, through a negotiated non-dilutive transaction with a former licensee in the Company's nano metals business. The capital is being used to advance the early stage cancer detection technology while the Company seeks strategic alternatives to monetize their nano-metals IP and assets. Additionally, the infusion of assets and dramatically improved balance sheet may possibly position the company for a future listing on a national exchange. As the Company eventually achieves important key milestones, such as licensing or partnerships, we believe its shares can surpass its recent 52-week high. The Company could eventually become a target for acquisition by a major conglomerate in the medical device industry. We believe MHTX offers a promising opportunity for speculative investors as it makes progress towards licensing of its technologies or joint venture partnerships.

Income Statement	FY 2013	FY2014	Sep-15	Balance Sheet	FY 2013	FY2014	Sep-15	Cash Flow Statement	FY 2013	FY2014	Sep-15
Revenue	652,000	642,000	37,000	Cash & cash equivalents	578,000	2,528,000	6,656,000	Operating Cash Flow	(964,000)	(2,535,000)	4,521,000
Operating Loss	(1,808,000)	(3,474,000)	(4,958,000)	Total Assets	1,861,000	3,633,000	14,231,000	Investing Cash Flow	(179,000)	(36,000)	(255,000)
Net Income / Loss	(1,928,000)	(3,805,000)	9,427,000	Total Liabilities	3,041,000	3,407,000	2,977,000	Financing Cash Flow	1,630,000	4,521,000	(138,000)
EPS	(0.00)	(0.01)	0.02	Total Shareholder's Equity	(2,238,000)	(832,000)	10,196,000	Cash at end of period	578,000	2,528,000	6,656,000

Figure 3: MHTX 1 Year Price Chart



Figure 1: MHTX 6 Month Price Chart



Sector: Nanotechnology
Industry: Medical Devices
Website: www.mhtx.com

Key Statistics

Price 12/30/2015	0.06
52 Week High	0.12
52 Week Low	0.04
Avg. Vol (3m)	163,352
Beta	-1.57
Market Cap (Interday)	33.22M
Market Cap/Book Value	3.26
Institutional Ownership (%)	0.00
Insider Ownership (%)	15.4
Shares Outstanding (M)	522.35M
Float (M)	441.58M
EPS(ttm)	0.02

Source: Cap IQ/Google Finance

Recent 2015 Highlights

- Dec. 14, 2015 Manhattan Scientifics expands collaboration with The University of Texas - MD Anderson Cancer Center.
- MHTX announced, October 26, 2015 the firm has been granted an additional Chinese patent alongside its US patents for detection, measurement and cell imaging technology.
- MHTX subsidiary - Senior Scientific, LLC, in August, 2015 was granted several U.S. patents for its MRX early stage cancer detection technology.
- August 26, 2015 MHTX announced initiation of a share repurchase program to be conducted over the next 12 months.
- MHTX announced February of 2015 that it reacquired its nanostructured metals intellectual property for a one-time payment of \$8 M cash, IP and other assets.
- In November of 2014, MHTX raised \$2M in equity for its MRX technology.
- Manhattan Scientifics and Los Alamos National Laboratory sign licensing partnership agreement.
- January 2015 Robert Proulx joins Senior Scientific, LLC as President and COO.

Corporate Contact Information

Manhattan Scientifics, Inc.
Marvin Maslow, Chairman / Founder
405 Lexington Ave. 26th Floor
New York, NY 10174
Phone: 917-923-3300
Website: www.mhtx.com
www.seniorscientific.com